Intensified post-discharge surveillance for Malignancies

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Fox Chase Cancer Center - Philadelphia, Philadelphia, PA
Malignancies+1 More
Intensified post-discharge surveillance - Procedure
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a randomized trial of intensified post-discharge surveillance (Intervention Arm) versus standard post-discharge surveillance (Control Arm).

Eligible Conditions

  • Malignancies
  • Surgery

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 90 days

30 days
30-day rate of death
30-day rate of hospital readmission after index surgery
30-day rate of readmission/visit to emergency department/death
30-day rate of unplanned Emergency Department visits
60 days
60-day rate of hospital readmission after index surgery
90 days
90-day rate of hospital readmission after index surgery

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Control Arm: Standard Perioperative Management
1 of 2
Intervention Arm: Intensified Post-Discharge Surveillance
1 of 2
Active Control
Experimental Treatment

880 Total Participants · 2 Treatment Groups

Primary Treatment: Intensified post-discharge surveillance · No Placebo Group · Phase 3

Intervention Arm: Intensified Post-Discharge Surveillance
Procedure
Experimental Group · 1 Intervention: Intensified post-discharge surveillance · Intervention Types: Procedure
Control Arm: Standard Perioperative Management
Procedure
ActiveComparator Group · 1 Intervention: Standard post-discharge surveillance · Intervention Types: Procedure

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 90 days
Closest Location: Fox Chase Cancer Center - Philadelphia · Philadelphia, PA
Photo of Philadelphia 1Photo of Philadelphia 2Photo of Philadelphia 3
2012First Recorded Clinical Trial
2 TrialsResearching Malignancies
76 CompletedClinical Trials

Who is running the clinical trial?

Fox Chase Cancer CenterLead Sponsor
214 Previous Clinical Trials
32,635 Total Patients Enrolled
5 Trials studying Malignancies
2,323 Patients Enrolled for Malignancies
Jason Castellanos, MDPrincipal InvestigatorFox Chase Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a diagnosis of breast cancer that is > 18 years old.
You are able to carry on all pre-disease performance without restriction.
You are scheduled for elective major cancer surgery (as listed in 4.1.
You are scheduled to be brought from your home (or normal living environment) to FCCC on the day of the index surgery (or day prior as scheduled admission) and you are scheduled to be brought to FCCC for surgery.
You are able to carry out work of a light or sedentary nature.
You are able to carry out all activities of daily living but unable to carry out any work activities.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.